Fill-Finish & Packaging

Lotte Biologics has big ambitions: new CDMO industry entrant unveils growth strategy

09-Feb-2023 By Jane Byrne

The South Korean player plans to expand its recently acquired US facility, to provide contract manufacturing services for Antibody Drug Conjugates (ADC), and to add drug product fill & finish facilities to establish a foothold in the North American...

Delpharm acquires injectable drug development center in the Netherlands from Dr Reddy's

05-Jan-2023 By Jane Byrne

France headquartered CDMO, Delpharm, has expanded its pharmaceutical development services with the acquisition of the Leiden Development Centre from Dr Reddy's in the Netherlands.

Polyplus acquires Belgian and French CDMOs as firm sees hike in demand for higher quality raw materials and increased regulatory scrutiny

15-Dec-2022 By Jane Byrne

France’s Polyplus has made two acquisitions of late, one to expand its plasmid DNA engineering technology and services portfolio, and another to enhance its GMP fill and finish capacities.

‘Innovators need to meet contract services partners sooner, plan much earlier and far further into development’

26-Oct-2022 By Rachel Arthur

A ‘significant shift’ is under way in global outsourcing strategies: with the sector moving away from phase-appropriate development in favor of a more forward-looking model – with experts advising starting the search for an outsourcing partner as early...

VGXI opens new HQ and manufacturing facility in Texas

24-Oct-2022 By Rachel Arthur

CDMO VGXI has officially opened its new headquarters and manufacturing facility in Conroe, Texas.

Increased demand for aseptic filling sees Cytiva boost manufacturing capacity in Vancouver

28-Jul-2022 By Jane Byrne

This week saw Cytiva open a new 126 200 ft2 (11,724 m2) site in the greater Vancouver area, Canada.

Samsung Biologics on track to open ‘super plant’ in October

28-Jul-2022 By Rachel Arthur

Construction of Samsung Biologics’ Plant 4 is on schedule with operations set to start in October, the company confirmed in its Q2 results this morning.

Bavarian Nordic gets US and EU approval for Denmark fill finish vaccine facility

28-Jul-2022 By Rachel Arthur

Bavarian Nordic A/S has received approvals from the US and EU regulatory authorities to manufacture its Jynneos/Imvanex smallpox and monkeypox vaccine at its fill and finish facility in Denmark.

WuXi Biologics to build CRDMO center in Singapore

21-Jul-2022 By Rachel Arthur

CDMO WuXi Biologics will invest $1.4bn in a 10 year investment plan to expand its research, development, and large-scale drug substance and drug product manufacturing capacity and capabilities in Singapore.

Spanish CDMO adapts production capabilities, boosts workforce to meet rising viral vector demand

27-Jun-2022 By Jane Byrne

VIVEbiotech has completed the latest expansion phase of its lentiviral vector manufacturing capabilities; the development is aimed at alleviating the viral vector bottleneck for advanced therapies.

bio 2022

ten23 adds manufacturing building in rapid build out

14-Jun-2022 By Ben Hargreaves

The newly launched CDMO plans to set up two new manufacturing lines, after expanding into a 5,000-square-meter manufacturing facility.

Novartis looks to work more strategically as CDMO

16-May-2022 By Jane Byrne

Novartis has recently set up a new contract development and manufacturing unit called Global Biotech Co-operations (GBTC).

Catalent to invest $350m to expand US drug substance and product manufacturing site

22-Apr-2022 By Jane Byrne

Catalent has announced a multi-year $350m investment at its facility in Bloomington, Indiana, to expand biologics drug substance and drug product manufacturing capabilities.

High Purity New England launches new manufacturing facility

18-Apr-2022 By Rachel Arthur

High Purity New England (HPNE), a supplier of single-use solutions for the biopharmaceutical industry, has launched its third facility.

Catalent buys UK vaccine manufacturing centre

07-Apr-2022 By Rachel Arthur

US company Catalent is acquiring the UK’s Vaccine Manufacturing and Innovation Centre in Harwell: a facility which had been planned to support COVID-19 and wider vaccine production and which is still under construction.

Vetter and Rentschler progress joint CDMO collaborative work

04-Apr-2022 By Jane Byrne

Vetter and Rentschler Biopharma are looking to boost the awareness and benefits of their strategic CDMO alliance.

Abzena secures $65m to expand production capacity, mammalian biologics site set to come online

31-Mar-2022 By Jane Byrne

Abzena, a global CDMO specializing in the integrated development and manufacture of complex biologics and bioconjugates, has secured $65M in new funding.

From textiles to therapies: North Carolina’s journey to a booming biotech hub

29-Mar-2022 By Rachel Arthur

While skills shortages present one of the main challenges to the biopharma industry, North Carolina believes its investments in the life science ecosystem have given it a ‘multiple decade jumpstart’ in building a successful biopharma hub for both manufacturing...

Moderna’s Australian mRNA manufacturing facility set to become operational in 2024

24-Mar-2022 By Rachel Arthur

Moderna has finalized a strategic partnership with the Australian government to build an mRNA manufacturing facility in Melbourne: which is expected to produce up to 100 million mRNA respiratory vaccine doses annually.

Catalent completes $30m expansion to biologics network

22-Mar-2022 By Ben Hargreaves

Catalent completes expansion of its biologics manufacturing network by upgrading its Limoges, France, location with additional capacity and the ability to produce large molecules.

Charles River expanding plasmid DNA and viral vector development in Europe

07-Mar-2022 By Jane Byrne

Charles River recently announced the expansion of its plasmid DNA and viral vector development and manufacturing capabilities in Europe; it says the move is to support the growing need of customers and to safeguard future supply.

WHO establishes global biomanufacturing training hub in Korea

25-Feb-2022 By Rachel Arthur

A global biomanufacturing training hub will be established in Korea to serve low- and middle-income countries wishing to produce biologicals such as vaccines, insulin, monoclonal antibodies and cancer treatments.

Valneva revives Scottish vaccine manufacturing plans

22-Feb-2022 By Rachel Arthur

Valneva has been awarded up to £20m ($27m) in R&D funding from Scottish Enterprise: which will be used to revive its plans to increase vaccine manufacturing in Scotland.

Piramal Pharma Solutions invests $75m in UK ADC and API facilities

10-Feb-2022 By Rachel Arthur

CDMO Piramal Pharma Solutions will expand capabilities of its Antibody-Drug Conjugate (ADC) facility in Grangemouth, Scotland; and invest in new Active Pharmaceutical Ingredient (API) infrastructure at its Morpeth, England facility.

Gerresheimer boosting glass vial production capacity globally

31-Jan-2022 By Jane Byrne

Gerresheimer is expanding its capacities for glass vials at the Wertheim site in southwestern Germany, and at two further sites in China and the US.

Recipharm leverages BSF capabilities at French site, secures vaccine packaging deal

28-Jan-2022 By Jane Byrne

Contract development and manufacturing organization (CDMO), Recipharm, says it has inked a deal with a top 10 big pharma company to support vaccine manufacturing from its facility in Kaysersberg, France.

Novo Holdings acquires blow-fill-seal manufacturing specialist Ritedose

10-Jan-2022 By Jane Byrne

Life science investor group, Novo Holdings, has agreed to buy Ritedose, the largest sterile CDMO in the US focused on advanced blow-fill-seal technology, from Hong-Kong based, AGIC Capital, and China’s Humanwell.

Biologics and vaccines focused CDMO sees investment from Piramal Pharma

03-Jan-2022 By Jane Byrne

Indian multinational, Piramal Pharma Limited (PPL), has taken a minority stake in Yapan Bio, a CDMO, based in Hyderabad, with expertise in biologics and vaccines.

Moderna to build mRNA vaccine manufacturing facility in Australia

14-Dec-2021 By Rachel Arthur

Moderna and the Australian government have announced an agreement in principle to build a mRNA vaccine manufacturing facility in Victoria, Australia: providing up to 100 million doses a year.

CDMO deals roundup: AGC Biologics, Halix and BioConnection support monoclonal antibody, gene therapy and vaccine projects

02-Dec-2021 By Jane Byrne

Several contract development and manufacturing organization (CDMO) supported biopharma projects have been flagged in the past month. We take a closer look.

Long lead times: Demand currently outstrips supply for contract manufacturing

30-Nov-2021 By Jane Byrne

As capital project delivery ramps back up to pre-pandemic levels over the coming months and years, the smaller biopharma players are looking outside their own resources for strategic manufacturing and research support, confirms a new market outlook from...

Speed, flexibility and innovation: Rethinking the way the biopharma industry operates

29-Nov-2021 By Jane Byrne

A new report reveals that “speed-to-market” has jumped up from a lower-ranking business driver before the pandemic to the top priority today for biopharma companies, overtaking cost-based considerations by a healthy margin.

CPhI Worldwide

Gerresheimer develops delivery device for drugs with higher viscosity

03-Nov-2021 By Jane Byrne

CPhI Worldwide will see Gerresheimer showcase its latest developments in primary packaging, drug delivery systems for newly developed biologics along with medical and diagnostic products.

Novartis signs new agreement with BioNTech for COVID-19 vaccine fill and finish

21-Oct-2021 By Rachel Arthur

Novartis has signed a new initial agreement with BioNTech for COVID-19 vaccine manufacturing: with its sterile manufacturing facilities in Ljubljana, Slovenia, to fill at least 24 million doses in 2022.

New Merck viral vector CDMO plant opens in California

14-Oct-2021 By Jane Byrne

Merck and subsidiary MilliporeSigma have completed work on their second Carlsbad, California-based facility.

Moderna to build $500m mRNA vaccine manufacturing facility in Africa

07-Oct-2021 By Rachel Arthur

Moderna will build a state-of-the-art mRNA facility in Africa, with the goal of producing up to 500 million vaccine doses a year.

‘Human error’ at CDMO blamed for contamination of Moderna COVID-19 vaccine

06-Oct-2021 By Jane Byrne

A probe has identified 'human error’ at the Spanish contract development and manufacturing organization, Rovi, as the reason for the presence of metal contaminants in Moderna COVID-19 vaccine doses, leading to Japanese authorities withdrawing 1.6...

Japan to take 150m doses of Takeda-produced Novavax shots, probe ongoing into deaths following inoculation with recalled Moderna vaccine lot

08-Sep-2021 By Jane Byrne

Japan’s health ministry is to secure 150 million doses of Novavax’ vaccine candidate that Takeda is producing. The Japanese government's purchasing agreement is subject to regulatory approvals.

Ardena buys Spain’s Idifarma in move to capitalize on emerging biotech segment

06-Sep-2021 By Jane Byrne

Ardena has acquired Idifarma, a contract manufacturer of niche and highly potent generic and innovative drugs, from Suanfarma; the deal enables it to expand across Southern Europe and supports its strategy to become a leading global CDMO.

BioNTech looks at mRNA vaccine manufacturing options in Rwanda and Senegal

29-Aug-2021 By Rachel Arthur

BioNTech is looking at establishing vaccine manufacturing capabilities in Rwanda and Senegal to support long-term vaccine supply in Africa.

EMA gives green light to additional mRNA COVID-19 vaccine manufacturing facilities

26-Aug-2021 By Rachel Arthur

The European Medicines Agency’s human medicines committee (EMA CHMP) has this week approved additional manufacturing capacity for Pfizer/BioNTech and Moderna COVID-19 vaccines.